Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Avalyn Pharma Inc.

Ticker
AVLN
Sector
Industry
Report date
November 15, 2026
Valye AI Score

60

High visibility
Recent developments
Recent developments summary

Recent developments highlight Avalyn Pharma's clinical progress in inhaled fibrosis therapies, corporate governance enhancements, and strong liquidity position.

Recent developments:
  • Avalyn Pharma added a former FDA executive to its board as AP01 and AP02 clinical trials progressed, enhancing regulatory expertise [N3].
  • The company completed enrollment for the MIST Phase 2b clinical trial targeting inhaled fibrosis therapies [N5].
  • Avalyn published Phase 1 data supporting lung-targeted delivery of its AP02 candidate in lung disease [N2].
  • AP01 demonstrated broad lung distribution in ERS 2026 in-silico modeling data [N4].
  • Avalyn outlined its inhaled fibrosis development strategy following its IPO, with pivotal data anticipated [N7].
  • The company reported strong liquidity with $333.7 million in current assets against $12.95 million in current liabilities as of September 30, 2026 [S1].
  • Avalyn reported a net loss of $29.7 million and basic and diluted EPS of -$0.67 for the quarter ended September 30, 2026 [S1].
Overview

Avalyn Pharma Inc. develops inhaled therapies targeting lung diseases, with a focus on fibrosis. Its pipeline includes AP01 and AP02 candidates, which are in clinical development stages. The company has recently completed enrollment in a Phase 2b trial (MIST) and published Phase 1 data supporting AP02's lung-targeted delivery. Avalyn's AP01 candidate demonstrated broad lung distribution in in-silico modeling presented at ERS 2026. The company strengthened its board by adding a former FDA executive, reflecting an emphasis on regulatory expertise. Avalyn completed its IPO and is advancing pivotal data generation for its inhaled fibrosis therapies. Financially, Avalyn maintains a strong liquidity position with substantial cash, short-term investments, and current assets relative to liabilities, though it reported a net loss and negative earnings per share for the latest quarter ending September 30, 2026.

Executive summary

Avalyn Pharma Inc. is a biopharmaceutical company focused on inhaled therapies for lung diseases, particularly inhaled fibrosis. The company has advanced clinical trials for its AP01 and AP02 drug candidates, including completion of MIST Phase 2b enrollment and publication of Phase 1 data supporting AP02. Avalyn added a former FDA executive to its board, signaling governance strengthening. As of September 30, 2026, Avalyn held $333.7 million in current assets against $12.95 million in current liabilities, with a strong liquidity position reflected in a current ratio of 25.76 and a cash ratio of 25.28. The company reported a net loss of $29.7 million and negative EPS of $0.67 for the quarter ended September 30, 2026. Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for AVLN

Bull case model:

Avalyn Pharma's advancement of inhaled fibrosis therapies through clinical trials, including completion of Phase 2b enrollment and publication of Phase 1 data, demonstrates progress in its pipeline. The company's strong liquidity position provides financial flexibility to support ongoing development. The addition of regulatory expertise to the board may facilitate efficient trial progression and regulatory interactions. Positive in-silico modeling data for AP01 and lung-targeted delivery data for AP02 support the scientific rationale for its therapies. These factors collectively indicate operational momentum in developing novel inhaled treatments for lung diseases.

Bear case model:

Avalyn Pharma operates in a high-risk clinical-stage biopharmaceutical sector with no disclosed revenues and ongoing net losses, including a $29.7 million loss in the latest quarter. The company faces typical risks of clinical trial outcomes, regulatory approvals, and market acceptance. Its financial position, while currently strong in liquidity, depends on continued capital access to fund development. The absence of detailed financial disclosures and commercial products limits visibility into sustainable business operations. Clinical and regulatory setbacks could materially impact the company's prospects and valuation.

Moat:

Avalyn Pharma's moat is primarily based on its specialized focus on inhaled therapies for lung diseases, particularly fibrosis, which is a complex therapeutic area with significant unmet medical needs. The company's development of proprietary drug candidates AP01 and AP02, supported by clinical trial progress and in-silico modeling data, may provide differentiation. Additionally, the addition of a former FDA executive to the board could enhance regulatory navigation capabilities. However, as a clinical-stage biopharmaceutical company without commercial products or revenues disclosed, its competitive advantages remain contingent on successful clinical development and regulatory approvals.

Risks overview
Risks summary
The biggest risks for Avalyn Pharma stem from clinical trial uncertainties, ongoing financial losses requiring capital, and regulatory approval challenges inherent in biopharmaceutical development.
Risks details:

• Clinical Development Risk: Avalyn's drug candidates AP01 and AP02 are in clinical trials, and their success depends on favorable trial outcomes and regulatory approvals, which are inherently uncertain.
• Financial Risk: Despite a strong liquidity position as of September 30, 2026, the company reported net losses and negative earnings per share, indicating ongoing cash burn and the need for additional financing.
• Regulatory Risk: The company's ability to navigate regulatory pathways is critical, and while it has added a former FDA executive to its board, regulatory approvals remain uncertain.
• Market and Commercialization Risk: Avalyn currently has no disclosed commercial products or revenues, and successful market adoption of its therapies depends on future approvals and competitive dynamics.

FINAL FORECAST FOR AVLN

Final take one line
Avalyn Pharma is a clinical-stage biopharmaceutical company focused on inhaled lung therapies with advancing clinical programs and strong liquidity but limited commercial visibility.
Final take 12 to 24 month view

Business trends: Progress in clinical trials for inhaled fibrosis therapies AP01 and AP02, publication of supporting Phase 1 data, and strategic board additions.
Execution milestones: Completion of MIST Phase 2b enrollment, ongoing pivotal data generation, and regulatory engagement supported by experienced board members.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, ongoing financial losses, and absence of commercial products.

Valye AI Visibility Research Score

High visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

60
LLM visibility overview
LLM Visibility known facts
  • Avalyn Pharma Inc. is a biopharmaceutical company focused on developing inhaled therapies for lung diseases.
  • The company is advancing inhaled fibrosis therapies, including AP01 and AP02 drug candidates.
  • Avalyn has completed enrollment for the MIST Phase 2b clinical trial related to inhaled fibrosis therapies.
  • Phase 1 data supporting lung-targeted AP02 in lung disease has been published.
  • AP01 shows broad lung distribution according to ERS 2026 in-silico modeling data.
  • Avalyn added a former FDA executive to its board as AP01 and AP02 trials progressed.
  • The company recently completed its IPO and outlined its inhaled fibrosis push with pivotal data ahead.
  • As of September 30, 2026, Avalyn had $145.4 million in cash and equivalents and $182.0 million in short-term investments, totaling $333.7 million in current assets against $12.95 million in current liabilities, resulting in a current ratio of 25.76 and a cash ratio of 25.28.
  • The company reported a net loss of $29.7 million and basic and diluted EPS of -$0.67 for the quarter ended September 30, 2026.
  • Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-09-28 | www.nasdaq.com | Add Up The Pieces: IHE Could Be Worth $116 | https://www.nasdaq.com/articles/add-pieces-ihe-could-be-worth-116
  • N2 | 2026-09-22 | www.nasdaq.com | Avalyn Publishes Phase 1 Data Supporting Lung-Targeted AP02 In Lung Disease | https://www.nasdaq.com/articles/avalyn-publishes-phase-1-data-supporting-lung-targeted-ap02-lung-disease
  • N3 | 2026-09-17 | www.nasdaq.com | Avalyn Pharma Adds Former FDA Executive To Board As AP01, AP02 Trials Progress | https://www.nasdaq.com/articles/avalyn-pharma-adds-former-fda-executive-board-ap01-ap02-trials-progress
  • N4 | 2026-09-09 | www.nasdaq.com | Avalyn's AP01 Shows Broad Lung Distribution In ERS 2026 In-Silico Modeling Data | https://www.nasdaq.com/articles/avalyns-ap01-shows-broad-lung-distribution-ers-2026-silico-modeling-data
  • N5 | 2026-08-12 | www.nasdaq.com | Avalyn Advances Inhaled Fibrosis Therapies; MIST Phase 2b Enrollment Completed | https://www.nasdaq.com/articles/avalyn-advances-inhaled-fibrosis-therapies-mist-phase-2b-enrollment-completed
  • N6 | 2026-08-10 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-halo-20-q2-results-fenc-avln-amlx-che
  • N7 | 2026-06-06 | www.nasdaq.com | Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead | https://www.nasdaq.com/articles/avalyn-pharma-outlines-inhaled-fibrosis-push-after-ipo-pivotal-data-ahead
  • N8 | 2026-05-04 | www.nasdaq.com | Monday 5/4 Insider Buying Report: AVLN, CSGP | https://www.nasdaq.com/articles/monday-5-4-insider-buying-report-avln-csgp
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine